ZRANB1: A Potential Drug Target and Biomarker (G54764)

Target Name: ZRANB1

NCBI ID: G54764

ZRANB1

ZRANB1: A Potential Drug Target and Biomarker

Zinc finger RNA binding proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in post-transcriptional gene regulation. These proteins have been identified as potential drug targets in the field of pharmacology due to their ability to modulate gene expression in response to various signaling pathways. One of the ZFPs that has garnered significant attention is ZRANB1, which has been shown to be involved in a wide range of physiological processes, including cell growth, differentiation, and survival.

ZRANB1: Structure and Function

The ZRANB1 protein is a 21-kDa RNA molecule that consists of a unique alternating double-stranded structure. It has five zinc fingers that are involved in binding to specific DNA sequences. ZRANB1 was first identified as a new gene encoding a protein that was expressed in various tissues and organs, including brain, heart, and muscle. The protein has been shown to play a role in regulating gene expression and has been implicated in the development and progression of various diseases, including cancer.

Functional assays have shown that ZRANB1 can modulate gene expression in a variety of ways. For example, it has been shown to upregulate the expression of genes involved in cell adhesion and migration, while downregulate the expression of genes involved in cell proliferation and survival. ZRANB1 has also been shown to play a role in regulating stem cell self-renewal and differentiative capacity.

Due to its involvement in these processes, ZRANB1 has potential as a drug target for a variety of diseases. For example, ZRANB1 has been shown to be involved in the development and progression of various types of cancer, including neurobladder cancer, breast cancer, and colorectal cancer. It has also been shown to be involved in diseases that involve inflammation, such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD).

In addition to its potential as a drug target, ZRANB1 has also been shown to be a potential biomarker for a variety of diseases. For example, it has been shown to be involved in the regulation of stem cell proliferation and differentiation, which could make it an useful biomarker for tracking the effectiveness of stem cell treatments. It has also been shown to be involved in the regulation of cell adhesion and migration, which could be useful for tracking the effectiveness of drugs that are designed to modulate these processes.

Targeting ZRANB1

The development of new drugs that target ZRANB1 is an exciting area of research with the potential to improve the treatment of a wide range of diseases. ZRANB1 has been shown to be involved in a variety of physiological processes, including cell growth, differentiation, and survival, which makes it an attractive target for drugs that are designed to modulate these processes.

One approach to targeting ZRANB1 is to use small molecules that can modulate its activity. This approach has been used to great effect in the development of drugs that target a wide range of protein kinases, including several that are currently in clinical use. Small molecules that can modulate ZRANB1 activity have been shown to be effective in a variety of settings, including cell-based assays and in animal models of disease.

Another approach to targeting ZRANB1 is to use antibodies that can specifically recognize and bind to ZRANB1. This approach has been used to study ZRANB1 function in a variety of cellular and biological systems, including cell-based assays and in animal models of disease. antibodies that can specifically recognize and bind to ZRANB1 have been shown to be highly effective in a variety of settings, including cell-based assays and in animal models of disease.

Conclusion

In conclusion, ZRANB1 is a protein that has significant potential as a drug target and biomarker. Its involvement in a wide range of physiological processes makes it an attractive target for drugs that are designed to modulate these processes

Protein Name: Zinc Finger RANBP2-type Containing 1

Functions: Ubiquitin thioesterase, which specifically hydrolyzes 'Lys-29'-linked and 'Lys-33'-linked diubiquitin (PubMed:22157957, PubMed:23827681, PubMed:25752573, PubMed:25752577). Also cleaves 'Lys-63'-linked chains, but with 40-fold less efficiency compared to 'Lys-29'-linked ones (PubMed:18281465). Positive regulator of the Wnt signaling pathway that deubiquitinates APC protein, a negative regulator of Wnt-mediated transcription (PubMed:18281465). Acts as a regulator of autophagy by mediating deubiquitination of PIK3C3/VPS34, thereby promoting autophagosome maturation (PubMed:33637724). Plays a role in the regulation of cell morphology and cytoskeletal organization (PubMed:21834987). Required in the stress fiber dynamics and cell migration (PubMed:21834987)

The "ZRANB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZRANB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets